Spinraza Den europeiske union - norsk - EMA (European Medicines Agency)

spinraza

biogen netherlands b.v. - nusinersen natrium - muskelatrofi, spinal - andre nervesystemet narkotika - spinraza er indisert for behandling av 5q spinal muskelatrofi.

Irinokabi 20 mg/ ml Norge - norsk - Statens legemiddelverk

irinokabi 20 mg/ ml

fresenius kabi oncology plc - irinotekanhydrokloridtrihydrat - konsentrat til infusjonsvæske, oppløsning - 20 mg/ ml

Pelmeg Den europeiske union - norsk - EMA (European Medicines Agency)

pelmeg

mundipharma corporation (ireland) limited - pegfilgrastim - nøytropeni - immunostimulants, - for å redusere varigheten av neutropenia og forekomsten av febrile neutropenia på grunn av kjemoterapi.

Libtayo Den europeiske union - norsk - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karsinom, squamous cell - antineoplastiske midler - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Aclasta 5 mg Norge - norsk - Statens legemiddelverk

aclasta 5 mg

abacus medicine a/s - zoledronsyremonohydrat - infusjonsvæske, oppløsning - 5 mg

Tecfidera 240 mg Norge - norsk - Statens legemiddelverk

tecfidera 240 mg

2care4 aps - dimetylfumarat - enterokapsel, hard - 240 mg

Tecfidera 240 mg Norge - norsk - Statens legemiddelverk

tecfidera 240 mg

orifarm as - dimetylfumarat - enterokapsel, hard - 240 mg

Aclasta 5 mg Norge - norsk - Statens legemiddelverk

aclasta 5 mg

2care4 aps - zoledronsyremonohydrat - infusjonsvæske, oppløsning - 5 mg

Tecfidera 120 mg Norge - norsk - Statens legemiddelverk

tecfidera 120 mg

orifarm as - dimetylfumarat - enterokapsel, hard - 120 mg

Byooviz Den europeiske union - norsk - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Øyemidler - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).